This is a parallel-group, prospective, randomized, controlled phase III trial to determine if high flow nasal therapy delivered via myAirvo 3 in addition to the usual COPD medical care increases the time to first moderate-severe exacerbation or all-cause mortality in patients with moderate to very severe COPD with recent exacerbation requiring hospitalization.
The myAirvo 3 is a humidifier with integrated flow generator designed to deliver air or oxygen via the Optiflow™ + Duet nasal cannula.
For more detailed information on this trial please click the link above to visit ClinicalTrials.gov